After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
The acquisition of Araris follows a 2023 discovery collaboration.
The company buys Belgium’s EsoBiotec for $425m.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
The Japanese group licenses sapablursen from Ionis for $280m.
